Literature DB >> 12269625

Voice quality changes following phonatory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease.

C A Baumgartner1, S Sapir, T O Ramig.   

Abstract

Perceptual ratings of hoarseness and breathiness were used to assess the efficacy of two intensive methods for treating dysarthrophonia in individuals with idiopathic Parkinson disease. One method emphasized phonatory-respiratory effort (the Lee Silverman Voice Treatment, LSVT) and the other emphasized respiratory effort alone (RET). Perceptual ratings were performed by two expert listeners based on random order presentation of the patients' pretreatment and posttreatment recordings of the "Rainbow Passage." The listeners were blinded to the patients and their treatment group. Statistically significant pretreatment to posttreatment improvement in hoarseness and breathiness was observed in the LSVT group but not in the RET group. The present findings are consistent with acoustic and physiologic findings reported previously, providing further evidence for the efficacy of the LSVT.

Entities:  

Mesh:

Year:  2001        PMID: 12269625     DOI: 10.1016/s0892-1997(01)00010-8

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  22 in total

1.  Effect of level of presentation to listeners on scaled speech intelligibility of speakers with dysarthria.

Authors:  Yunjung Kim; Christina Kuo
Journal:  Folia Phoniatr Logop       Date:  2012       Impact factor: 0.849

Review 2.  Targeted exercise therapy for voice and swallow in persons with Parkinson's disease.

Authors:  John A Russell; Michelle R Ciucci; Nadine P Connor; Timothy Schallert
Journal:  Brain Res       Date:  2010-03-15       Impact factor: 3.252

3.  The effect of increased vocal intensity on interarticulator timing in speakers with Parkinson’s disease: a preliminary analysis.

Authors:  Kelly Richardson; Joan E Sussman; Elaine T Stathopoulos
Journal:  J Commun Disord       Date:  2014 Nov-Dec       Impact factor: 2.288

4.  Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus.

Authors:  Jennifer Spielman; Leslie Mahler; Angela Halpern; Phllip Gilley; Olga Klepitskaya; Lorraine Ramig
Journal:  J Commun Disord       Date:  2011-06-13       Impact factor: 2.288

5.  Vocal function exercises for normal voice: The effects of varying dosage.

Authors:  Maria Bane; Vrushali Angadi; Emily Dressler; Richard Andreatta; Joseph Stemple
Journal:  Int J Speech Lang Pathol       Date:  2017-09-19       Impact factor: 2.484

6.  Listener Perception of Monopitch, Naturalness, and Intelligibility for Speakers With Parkinson's Disease.

Authors:  Supraja Anand; Cara E Stepp
Journal:  J Speech Lang Hear Res       Date:  2015-08       Impact factor: 2.297

Review 7.  Comparison of speech and language therapy techniques for speech problems in Parkinson's disease.

Authors:  Clare P Herd; Claire L Tomlinson; Katherine H O Deane; Marian C Brady; Christina H Smith; Catherine M Sackley; Carl E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

8.  Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.

Authors:  L O Ramig; S Sapir; S Countryman; A A Pawlas; C O'Brien; M Hoehn; L L Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

9.  Increased vocal intensity due to the Lombard effect in speakers with Parkinson's disease: simultaneous laryngeal and respiratory strategies.

Authors:  Elaine T Stathopoulos; Jessica E Huber; Kelly Richardson; Jennifer Kamphaus; Devan DeCicco; Meghan Darling; Katrina Fulcher; Joan E Sussman
Journal:  J Commun Disord       Date:  2013-12-28       Impact factor: 2.288

10.  The coordination of breathing and swallowing in Parkinson's disease.

Authors:  Roxann Diez Gross; Charles W Atwood; Sheryl B Ross; Kimberly A Eichhorn; Joan W Olszewski; Patrick J Doyle
Journal:  Dysphagia       Date:  2007-11-20       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.